Functional Pulmonary Capillary Surface Area in BPA for CTEPH
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorJewish General Hospital
About this trial
Chronic thromboembolic pulmonary hypertension \[CTEPH\] is caused by pulmonary emboli that have enlarged in pulmonary arteries and have become organized into the vessel wall. Many patients with CTEPH are treated with balloon pulmonary angioplasty \[BPA\] which mechanically opens the narrow pulmonary arteries. It is unclear how much downstream functional pulmonary capillary surface area \[FCSA\] is recovered during BPA. The investigators plan to measure FCSAIn CTEPH patients, before and after a session of BPA.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
All patients eligible for balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension
Disqualifiers
Treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers,
Presence of patent foramen ovale
Trial design
Design model
Single group
Treatments tested in this trial
Measurement of pulmonary functional capillary surface area
Other interventionMeasurement of transpulmonary metabolism of trace injected doses of benzoyl-Phe-Ala-Pro
Treatment groups
40 Participants
are divided into 1 treatment groupGroup A: Pre and post BPAExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Change in pulmonary functional capillary surface area
Measurement of transpulmonary metabolism of benzoyl-Phe-Ala-Pro
Time frame
4 hoursSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov